From Wound to Wellness, 5 Top Diabetic Foot Ulcer Treatment Companies Healing Pain Point

Diabetes is a chronic illness that affects millions of people across the globe, and it can have severe consequences for foot health. For diabetic patients, even the most minor of wounds can become a major problem and need attentive care and nursing. Diabetic Foot Ulcer (DFU) has become a main public health concern, resulting in a lower quality of life, high healthcare spending, and extended hospital stays for patients with diabetes. Seeking the right diabetic foot ulcer treatment is essential for avoiding complications and encouraging healing. An increase in diabetes prevalence, geriatric population, rapid innovations in wound care, and growing consciousness and screenings for diabetic foot ulcers are propelling market expansion. With cutting-edge diabetic wound care, appropriate offloading, infection control, and blood sugar management, healing is possible.

With numerous renowned and small players, the global market for diabetic foot ulcer treatment displays a competitive and fragmented landscape. Top participants such as 3M, Smith+Nephew, Mölnlycke Health Care AB, Convatec Inc., and Coloplast A/S stand out, holding a considerable share.

As per a report by Fortune Business Insights™, the market for diabetic foot ulcer treatment reached USD 8.83 billion in 2024 and is expected to reach USD 14.37 billion by 2032 with a CAGR of 6.3% from 2025 to 2032. The market size is anticipated to reach USD 9.36 billion in 2025.

Fortune Business Insights™ Profiles Top 5 Diabetic Foot Ulcer Treatment Companies

1) 3M

Headquartered in the U.S., 3M is one of the major diabetic foot ulcer treatment companies. It registered a revenue of USD 32.68 billion and 16%-18% market share in 2023. The company works under four segments transportation and electronics, safety and industrial, healthcare, and consumer. The healthcare business segment comprises products for various areas, including wound care, healthcare procedure coding and reimbursement software, skin, and infection prevention products and solutions, dentistry and orthodontic solutions, and filtration and purification systems. In January 2024, 3M received an award of USD 34.2 million from the U.S. Army Medical Research Acquisition Activity for developing a new range of products for infection prevention, wound management, and wound healing.

2) Smith+Nephew

Smith+Nephew was founded in 1856 in the U.K. and held the second-largest share of the global market for diabetic foot ulcer treatment in 2023 with a valuation of USD 5.55 billion in 2023. It has innovative wound management products with bio actives, wound care dressings, and wound devices for the treatment of diabetic foot ulcers. These products are generally produced at plants in the U.S., China, and the U.K. With production units across eight different countries, Smith+Nephew boosts its reputation in the global market. The company stands out prominent in the U.S., Japan, Australia, Canada, New Zealand, and Europe. In April 2024, Smith+Nephew introduced the RENASYS EDGE NPWT system, a lightweight and compact device utilized to treat chronic wounds, such as diabetic foot ulcers.

3) Mölnlycke Health Care AB

A Swedish medical device company, Mölnlycke Health Care is based in Gothenburg and active internationally. It is the third-largest diabetic foot ulcer treatment provider in the market. The company excels in wound care solutions, operating under four key areas: Wound Care, ORS (Operating Room Solutions), Gloves, and Antiseptics. Its portfolio covers everything from advanced dressings to negative pressure therapy systems, supporting patients with burns, surgical incisions, and chronic wounds. Mölnlycke’s USD 2.08 billion revenue in 2023 is backed by its 16 manufacturing units across Europe, North America, and Asia. In April 2024, Mölnlycke Health Care AB acquired P.G.F. Industry Solutions GmbH. The acquired company is involved in the production of Granudacyn, a specialized range of products for wound care and moisturizing treatment.

4) Convatec Inc.

Established in the U.K., Convatec Inc. is the fourth-key player in the global market. The company reached a valuation of USD 2.14 billion in 2023. Being a powerhouse in the wound care segment, Convatec Inc. offers alginates, hydrogel, hydrocolloid dressings, gelling fiber dressings, and others. In March 2023, Convatec Inc. achieved the U.S. FDA approval for InnovaBurn, a cutting-edge placental extracellular matrix medical device. It is engineered to support healing in difficult wounds, including second-degree burns and stubborn diabetic ulcers.

5) Coloplast A/S

Initiated in Denmark in 1957, Coloplast A/S is a Danish international company that develops, produces and markets medical devices and services associated with ostomy, urology, continence, and wound care. It witnessed a comparatively lesser market share. The company was valued at USD 3.56 billion in 2023. Its cutting-edge wound care division contains four segments such as skin care, contract manufacturing, advanced dressings, and biologics. Coloplast A/S maintains its robust presence across 140 countries being one of the top producers of wound care products. In January 2024, Coloplast A/S launched the Biatain Silicone Fit for wound management and pressure injury prevention to boost the product offerings in the U.S.

Smart Soles, Stronger Steps: Tech-Driven Solutions for Diabetic Foot Ulcers

With the rapid integration of Artificial Intelligence (AI), several advancements have happened in the screening, detection, and treatment of diabetic foot ulcers. AI-based software and applications have been created to support healthcare experts and patients. These systems are trained & tested using DFU datasets. Technological innovations in diabetic wound management and rising demand for skin grafting devices present profitable prospects to market players. Healthcare specialists emphasize offering more efficient treatment for diabetic foot ulcers to improve patient outcomes. Key players offer products that match other aspects of wound care, infection prevention, or patient management. Furthermore, leading companies create products precisely designed to tackle the unique challenges related to diabetic foot ulcers.

Smart footwear and accessories are gaining traction for diabetic foot ulcer treatments. They support post-ulcer healing and avert ulcers from forming or recurring in high-risk patients. High localized foot temperature is considered an early sign of tissue inflammation, a precursor to ulcer development. Smart socks collect data and share it to a smartphone app and enables healthcare experts and patients to take immediate action. A surge in research and studies about smart footwear and accessories are expected to inspire diabetic foot ulcer treatment companies to launch enhanced quick healing solutions.